GTx (GTXI) +10.3% premarket after saying the FDA removed its Full Clinical Hold on its Investigational New Drug application for prostate cancer treatment Capesaris. During Q3, GTXI expects to initiate a Phase II clinical study of Capesaris as a secondary hormonal therapy in men with certain kinds of prostate cancer. (also: earnings)
GTx (GTXI) +10.3% premarket after saying the FDA removed its Full Clinical Hold on its...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs